Abstract Library

#4579 Real-world effectiveness of lanreotide autogel in patients with advanced gastroenteropancreatic neuroendocrine tumours with antigen Ki-67 proliferation index above and below 10%: The KINETICS study

Introduction: The somatostatin analogue lanreotide is an established treatment option for patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) with a Ki-67 proliferation index (Ki-67)

Conference:

Presenting Author: Vandamme T

Authors: Vandamme T, Gerard L, Del Olmo-Garcia M, de Mestier L, Kiesewetter B,

Keywords: effectiveness, gastroenteropancreatic neuroendocrine tumour, GEP-NET, Ki-67 proliferation index, Ki-67, lanreotide, somatostatin analogue, somatostatin, real-world,

#4431 Systemic treatment in metastatic pheochromocytomas and paragangliomas: Optimal moment for starting and outcomes of a multicentre Spanish cohort

Introduction: Pheochromocytomas (PHEOs) and paragangliomas (PGLs), collectively referred to as PPGLs, are relatively rare endocrine tumours with significant clinical variability and metastatic behaviour. Treatment strategies must be tailored individually due to the heterogeneity in their behaviour.

Conference:

Presenting Author: Del Olmo-García M

Authors: Hernández-Rienda L, Contreras-Saldarriaga J, Hernando Cubero J, García Alvarez A, Prado-Wohlwend S,

Keywords: Pheochromocytoma, paraganglioma, PPGL, metastatic, SSA, Radionuclide, chemotherapy,

#4338 Spot urine 5-HIAA creatinine ratio is comparable to 24hr urine collection for diagnosis of carcinoid syndrome

Introduction: Carcinoid syndrome (CS) constitutes up to 20% of functional neuroendocrine neoplasms and can lead to carcinoid crisis (CC), a potentially fatal complication during invasive procedures. Urine 5-hydroxyindoleacetic acid (5HIAA) is the preferred diagnostic biomarker for CS and prognostic marker for CC. 5HIAA is collected over 24-hours with strict dietary restriction for the 2 days prior as well as the day of the collection. False positive and negative results can occur due to under and over-collection. Patient inconvenience also contributes to the low request rate of this test.

Conference:

Presenting Author: Kong G

Authors: Chiang C, Gamage I, Del Olmo-Garcia M, Pasanen L, Wong H,

Keywords: carcinoid syndrome, carcinoid crisis, urine 5-HIAA, biomarker,

#4303 Carcinoid crisis: Insights from an ENETS Center of Excellence

Introduction: Neuroendocrine neoplasms (NENs) are rare tumours, with up to 30% being functional and associated with carcinoid syndrome (CS). CS commonly presents with flushing, diarrhoea, and hemodynamic instability, and can progress to carcinoid crisis (CC), a severe, potentially fatal complication during surgery or other invasive procedures. The use of prophylactic octreotide infusion peri-operatively remains controversial. The lack of a universal CC definition also poses a challenge for standardised outcome assessments.

Conference:

Presenting Author: Del Olmo-Garcia M

Authors: Del Olmo-Garcia M, Kong G, Wong H, Michael M, Ismail H,

Keywords: carcinoid syndrome, carcinoid crisis, somatostatin analogue, peri-operative management,

#4069 Impact of nutritional status in the quality of life (QoL) of patients with advanced gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) in Spain: NUTRIGETNE Study

Introduction: Prevalence of malnutrition and sarcopenia is high among patients with advanced GEP-NENs and may significantly decrease response to therapy and impair QoL.

Conference:

Presenting Author:

Authors: Del Olmo-García M, Garcia-Carbonero R, Hernando J, Pérez-Wert P, Suarez Gutiérrez L,

Keywords: nutritional status, Gastroenteropancreatic, Neuroendocrine neoplasm, Sarcopenia, Malnutrition,